Malte Kircher1,2, Sandra Ihne2,3, Joachim Brumberg1, Caroline Morbach2,4, Stefan Knop3, K Martin Kortüm3, Stefan Störk2,4, Andreas K Buck1, Theresa Reiter5, Wolfgang R Bauer4, Constantin Lapa1. 1. Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97078, Würzburg, Germany. 2. Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany. 3. Department of Internal Medicine II, Hemato-Oncology, University Hospital Würzburg, Würzburg, Germany. 4. Department of Internal Medicine I, Cardiology, University Hospital Würzburg, Oberdürrbacher Str. 6, 97078, Würzburg, Germany. 5. Department of Internal Medicine I, Cardiology, University Hospital Würzburg, Oberdürrbacher Str. 6, 97078, Würzburg, Germany. Reiter_T@ukw.de.
Abstract
PURPOSE: Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid imaging using positron emission tomography/computed tomography (PET/CT) has emerged. The aim of this study was to examine the performance of 18F-florbetaben-PET/CT in detection of CA, and compare it to echocardiography (echo), cardiac MRI (CMR) and scintigraphy. Additionally, the use of 18F-florbetaben-PET/CT for quantification of amyloid burden and monitoring of treatment response was assessed. METHODS: Twenty-two patients with proven (n = 5) or clinical suspicion (n = 17) of CA underwent 18F-florbetaben-PET/CT for diagnostic work-up. Qualitative and quantitative assessment including calculation of myocardial tracer retention (MTR) was performed, and compared to echo (n = 20), CMR (n = 16), scintigraphy (n = 16) and serologic biomarkers (NT-proBNP, cTnT, free light chains). In four patients, follow-up PET/CT was available (after treatment initiation, n = 3; surveillance, n = 1). RESULTS: PET demonstrated myocardial 18F-florbetaben retention consistent with CA in 14/22 patients. Suspicion of CA was subsequently dropped in all eight PET-negative patients. Amyloid subtypes showed characteristic retention patterns (AL > AA > ATTR; all p < 0.005). MTR correlated with morphologic and functional parameters, as measured by CMR and echo (all r| > 0.47|, all p < 0.05), but not with cardiac biomarkers. Changes in MTR from baseline to follow-up corresponded well to treatment response, as assessed by cardiac biomarkers and performance status. CONCLUSIONS: Imaging of cardiac amyloidosis (CA) with 18F-florbetaben-PET/CT is feasible and might be useful in differentiating CA subtypes.
PURPOSE:Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid imaging using positron emission tomography/computed tomography (PET/CT) has emerged. The aim of this study was to examine the performance of 18F-florbetaben-PET/CT in detection of CA, and compare it to echocardiography (echo), cardiac MRI (CMR) and scintigraphy. Additionally, the use of 18F-florbetaben-PET/CT for quantification of amyloid burden and monitoring of treatment response was assessed. METHODS: Twenty-two patients with proven (n = 5) or clinical suspicion (n = 17) of CA underwent 18F-florbetaben-PET/CT for diagnostic work-up. Qualitative and quantitative assessment including calculation of myocardial tracer retention (MTR) was performed, and compared to echo (n = 20), CMR (n = 16), scintigraphy (n = 16) and serologic biomarkers (NT-proBNP, cTnT, free light chains). In four patients, follow-up PET/CT was available (after treatment initiation, n = 3; surveillance, n = 1). RESULTS: PET demonstrated myocardial 18F-florbetaben retention consistent with CA in 14/22 patients. Suspicion of CA was subsequently dropped in all eight PET-negative patients. Amyloid subtypes showed characteristic retention patterns (AL > AA > ATTR; all p < 0.005). MTR correlated with morphologic and functional parameters, as measured by CMR and echo (all r| > 0.47|, all p < 0.05), but not with cardiac biomarkers. Changes in MTR from baseline to follow-up corresponded well to treatment response, as assessed by cardiac biomarkers and performance status. CONCLUSIONS: Imaging of cardiac amyloidosis (CA) with 18F-florbetaben-PET/CT is feasible and might be useful in differentiating CA subtypes.
Entities:
Keywords:
Amyloid imaging; Diagnosis; Heart; Response assessment; Retention index
Authors: A Foli; G Palladini; R Caporali; L Verga; P Morbini; L Obici; P Russo; G Sarais; S Donadei; C Montecucco; G Merlini Journal: Amyloid Date: 2011-06 Impact factor: 7.141
Authors: Morie A Gertz; Ray Comenzo; Rodney H Falk; Jean Paul Fermand; Bouke P Hazenberg; Philip N Hawkins; Giampaolo Merlini; Philippe Moreau; Pierre Ronco; Vaishali Sanchorawala; Orhan Sezer; Alan Solomon; Giles Grateau Journal: Am J Hematol Date: 2005-08 Impact factor: 10.047
Authors: Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan Journal: JACC Cardiovasc Imaging Date: 2010-02
Authors: Bethany A Austin; W H Wilson Tang; E Rene Rodriguez; Carmela Tan; Scott D Flamm; David O Taylor; Randall C Starling; Milind Y Desai Journal: JACC Cardiovasc Imaging Date: 2009-12
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Walter Noordzij; Johan Bijzet; Bouke P C Hazenberg; Hans L A Nienhuis Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-23 Impact factor: 9.236
Authors: Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita Journal: Arq Bras Cardiol Date: 2021-09 Impact factor: 2.000
Authors: Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu Journal: J Nucl Cardiol Date: 2022-07-21 Impact factor: 3.872
Authors: M F Santarelli; D Genovesi; M Scipioni; V Positano; B Favilli; A Giorgetti; G Vergaro; L Landini; M Emdin; P Marzullo Journal: J Nucl Cardiol Date: 2021-04-16 Impact factor: 3.872
Authors: Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras Journal: Diagnostics (Basel) Date: 2021-05-30